24.0202:  A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician Choice in 3L+ Advanced or Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)

Principal Investigator: Abigail Chan, MD

Phase:  III

Description:  This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).

ClinicalTrials.gov:  https://clinicaltrials.gov/study/NCT06356311?term=NCT06356311&rank=1

23.0823:  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) 

Principal Investigator: Abigail Chan, MD 

Phase:  III 

Description:  This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

More Info:  https://clinicaltrials.gov/study/NCT05174169?term=NCT05174169&rank=1

23.0042:  A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications 

Principal Investigator: Rebecca Redman, MD 

Phase:  I/II 

Description:  DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). A combination therapy cohort will be opened for enrollment, DF9001 + nivolumab. The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors. 

More info: https://clinicaltrials.gov/study/NCT05597839?term=NCT05597839&rank=1

22.1054:  A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection. 

Principal Investigator: Vivek Sharma, MD, FACP 

Phase:  II 

Description:  This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer. 

More info:  https://clinicaltrials.gov/study/NCT04486378?term=NCT04486378&rank=1

22.0814: A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Principal Investigator: Vivek Sharma, MD, FACP

Phase:  II

Description:  Multi-center, open label, randomized, 2-parallel arm, phase IIb study of nab-paclitaxel and gemcitabine as SoC plus/minus VCN-01 in patients with metastatic pancreatic cancer. VCN-01 is a genetically modified adenovirus characterised by the presence of four independent genetic modifications on the backbone of the wild-type human adenovirus serotype 5 (HAd5) genome that confer tumor selective replication and antitumor activity. Approximately 92 patients in sites in North America and European Union (EU) will be recruited and randomized in a 1:1 ratio to one of two treatment arms (i.e., approximately 46 patients per treatment arm):

More Info: https://clinicaltrials.gov/ct2/show/NCT05673811?term=NCT05673811&draw=2&rank=1  

22.0393: A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma

Principal Investigator: Vivek Sharma, MD, FACP

Phase: I

Description: The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7.All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be open label and will enroll participants at increasing dose levels of BXQ-350 in order to determine the Stage 2 dose. Stage 2 will be blinded; participants will receive BXQ-350 at the established Stage 1 dose or placebo.

More Info: https://clinicaltrials.gov/ct2/show/NCT05322590?term=NCT05322590&draw=2&rank=1

22.0024: A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal CarcinomaA Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

Principal Investigator: Vivek Sharma, MD, FACP

Phase: III

Description: First-line treatment of participants with metastatic squamous cell carcinoma of the esophagus

More Info: https://clinicaltrials.gov/ct2/show/NCT04949256?term=NCT04949256&draw=2&rank=1

21.0920:  Study Title:  A Phase 1 Open-label, Multicenter, Dose- ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1 

Principal Investigator: Rebecca Redman, MD 

Phase:  This is a Phase 1 first-in-human, open-label, dose escalation and dose expansion study of MT-6402 that will be conducted in 2 parts. Part A is designed to estimate the maximum tolerated dose (MTD) and Part B is designed to identify the RP2D.I 

Description:  This is a Phase 1 first-in-human, open-label, dose escalation and dose expansion study of MT-6402 that will be conducted in 2 parts. Part A is designed to estimate the maximum tolerated dose (MTD) and Part B is designed to identify the RP2D. 

ClinicalTrials.gov:  https://clinicaltrials.gov/study/NCT04795713?term=NCT04795713&rank=1

20.0927:  PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER

Principal Investigator: Adam Rojan, MD

Phase:  III

Description:  This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

More info:  https://clinicaltrials.gov/ct2/show/NCT04340141?term=NCT04340141&draw=2&rank=1

 08.0388 - Protocol for the Cancer Database and Specimen Repository (CDSR) at the Brown Cancer Center (Previous Lung Repository).

Principal Investigator: Rebecca Redman, M.D.

Description: The mission of the Cancer Database and Specimen Repository (CDSR) is to collect clinical information and samples of human specimens from cancer patients and from control patients for research, and to distribute specimens to researchers for the advancement of science.